





APPENDIX A

NUMBER OF AGES-SEX SPECIFIC DEATH RATE
PER 1,000 POPULATIONS, 2004

APPENDIX A

NUMBER OF AGES-SEX SPECIFIC DEATH RATE PER 1,000 POPULATIONS, 2004

Table 29 Number of Ages-Sex Specific Death Rate per 1,000 Populations, 2004*

Age (Year)		Rate	Age (Year)		Rate	Age (Year)		Rate
0 - 4	Male	2.4	25 - 29	Male	3.4	50 - 54	Male	9.5
	Female	2.0		Female	1.5		Female	5.0
5 - 9	Male	0.6	30 - 34	Male	4.4	55 - 59	Male	12.9
	Female	0.4		Female	1.8		Female	7.8
10 - 14	Male	0.6	35 - 39	Male	4.9	60 - 64	Male	17.3
	Female	0.4		Female	1.9		Female	11.1
15 - 19	Male	2.1	40 - 44	Male	5.7	65 - 69	Male	25.2
	Female	0.6		Female	2.3		Female	16.8
20 - 24	Male	2.6	45 - 49	Male	7.0	70 ⁺ and over	Male	59.1
	Female	0.8		Female	3.3		Female	51.0

*Collected and Analyzed by Health Information Group, Bureau of Health Policy and Strategy
Ministry of Public Health Thailand. Retrieved from "http://203.157.19.191/input_bps.htm"



APPENDIX B

TRANSITION PROBABILITIES OF DEATH FROM DIALYSIS

Table 30 Transition probabilities of death from dialysis*

Year after 1 st dialysis	Cumulative Death	Transition probability of death in a year
0	0.09	0.09
1	0.16	0.077
2	0.23	0.083
3	0.3	0.091
4	0.36	0.086
5	0.43	0.109
6	0.49	0.105
7	0.54	0.098
8	0.59	0.109
9	0.6	0.024
10	0.64	0.100
11	0.68	0.111
12	0.71	0.094
13	0.79	0.276

* Hemodialysis and peritoneal dialysis is not different. Data calculated from Thailand registry of renal replacement therapy 1997 -2003



APPENDIX C

DIABETES COMPLICATIONS COSTS CALCULATED FROM
BUDDHACHINARAJ HOSPITAL DATABASE

APPENDIX C

DIABETES COMPLICATIONS COSTS CALCULATED FROM BUDDHACHINARAJ HOSPITAL DATABASE

Table 31 Diabetes complications costs calculated from Buddhachinaraj hospital database

Complications	Costs (Baht)						
	Mean	SD	Median	Percentile			
				2.5	25	75	97.5
MI 1st year	67,653	84,859	41,603	1,878	17,488	80,650	360,158
MI following years	27,447	13,585	41,015	0	0	36,768	176,773
Angina 1st year	67,192	104,765	28,777	1,869	14,706	71,719	473,948
Angina following years	32,323	59,827	12,653	0	0	42,838	137,117
Stroke 1st year	63,984	142,725	20,797	173	7,052	49,242	675,637
Stroke following years	31,996	67,808	9,058	0	0	32,255	289,615
CHF 1st year	60,801	88,701	39,076	1,645	14,051	73,104	341,289
CHF following years	24,779	44,193	7,246	0	0	29,034	161,675
Neuropathy 1st year	21,515	37,419	8,618	182	4,140	23,839	137,645
Neuropathy following years	24,034	47,582	8,971	0	3,021	25,114	159,018
Amputation event	76,688	81,507	48,602	9,675	26,325	97,986	318,778
Ketoacidosis event	42,375	62,255	19,114	139	5,590	57,715	233,272
Lactic acidosis event	40,510	37,440	24,616	5,821	16,248	58,156	158,679
Hypoglycemic event	12,472	22,101	7,677	302	4,595	13,114	54,992
Gangrene (monthly based)	62,245	82,666	38,926	3,122	19,974	68,263	451,150
Ulcer (monthly based)	8,371	10,968	2,496	170	687	15,760	34,330

APPENDIX D

INCREMENTAL COST-EFFECTIVENESS RATIO USING MEDIAN DIABETES
COMPLICATION COST CALCULATED FROM
BUDDHACHINARAJ HOSPITAL

มหาวิทยาลัยพระนคร

APPENDIX D

INCREMENTAL COST-EFFECTIVENESS RATIO USING MEDIAN DIABETES COMPLICATION COST CALCULATED FROM BUDDHACHINARAJ HOSPITAL

Table 32 Incremental cost-effectiveness ratio using median diabetes complication cost
calculated from Buddhachinaraj hospital

	Pioglitazone group	Rosiglitazone group
Total lifetime cost (Baht) : Mean (SD)	374,904 (498, 756)	333,524(453,865)
Incremental cost per life expectancy (Baht per life year gained)	137,746	
Incremental cost per QALE (Baht per quality adjusted life year gained)	191,008	



APPENDIX E

CUMULATIVE COST OF 40 YEARS TIME HORIZON

APPENDIX E

CUMULATIVE COST OF 40 YEARS TIME HORIZON




Figure 13 Cumulative cost of 40 years time horizon

APPENDIX F

CUMULATIVE INCIDENCE OF CARDIOVASCULAR DISEASE OF THE
PIOGLITAZONE GROUP AND THE ROSIGLITAZONE GROUP

APPENDIX F

CUMULATIVE INCIDENCE OF CARDIOVASCULAR DISEASE OF THE PIOGLITAZONE GROUP AND THE ROSIGLITAZONE GROUP




Figure 14 Cumulative incidence of congestive heart failure




Figure 15 Cumulative incidence of myocardial infarction




Figure 16 Cumulative incidence of angina



APPENDIX G

BREAKDOWN OF COSTS AT THE END OF SIMULATION

APPENDIX G

BREAKDOWN OF COSTS AT THE END OF SIMULATION




Figure 17 Breakdown of costs at the end of simulation



APPENDIX H

CUMULATIVE INCIDENCE OF DIABETES COMPLICATIONS
AT THE END OF 40 YEARS SIMULATION

มหาวิทยาลัยพระศรี

APPENDIX H

CUMULATIVE INCIDENCE OF DIABETES COMPLICATIONS AT THE END OF 40 YEARS SIMULATION




Figure 18 Cumulative incidence of eye disease (%)




Figure 19 Cumulative incidence of cardiovascular disease (%)




Figure 20 Cumulative incidence of renal disease (%)




Figure 21 Cumulative incidence of ulcer and amputation (%)